127349-68-2

Usage

InChI:InChI=1/C11H15.BrH.Mg/c1-9-5-7-10(8-6-9)11(2,3)4;;/h5-8H,1H2,2-4H3;1H;/q;;+1/p-1/rC11H15BrMg/c1-11(2,3)10-6-4-9(5-7-10)8-13-12/h4-7H,8H2,1-3H3

Upstream product

• 18880-00-7 1-(bromomethyl)-4-(1,1-dimethylethyl)benzene 
• 7439-95-4 magnesium 
• 362-08-3 2-methoxyestrone 

Downstream Products

• 1126428-46-3 (S)-tert-butyl-2-(2-(4-tert-butylphenyl)acetyl)pyrrolidine-1-carboxylate 
• 1251843-06-7 Methyl 2-(4-tert-butylbenzyl)-4-((tert-butyldimethylsilyloxy)methyl)pyridine-1(2H)-carboxylate 
• 871251-14-8 (R,S)-(4-tert-butyl-phenyl)-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yl]-methanol 
• 134616-36-7 4-(4-(tert-butyl)benzyl)pyridine 
• 922501-10-8 [3-(4-tert-butyl-benzyl)-oxetan-3-yl]-acetic acid ethyl ester 
• 114378-07-3 1-tert-Butyl-4-trimethylsilylmethylbenzene 
• 112191-50-1 p-tert-butyl-α-<(chloromethyl)dimethylsilyl>toluene 

Relevant academic research and scientific papers

HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.

17-Aryl linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase

There is provided a compound comprising a steroidal ring system and a group R1 selected from any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the D ring of the steroidal ring system is substituted by a group R2 of the formula —L—R3, wherein L is an optional linker group and R3 is an aromatic hydrocarbyl group.